Inventor · disambiguated record
Mary Struthers
Also filed as: STRUTHERS MARY
12 granted patents·7 pending applications·45 citations·filing 2005–2024
90Inventor score
Top patents by PatentIndex Score
19 records- 0196US11926673B2Antagonistic CD40 monoclonal antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Mar 12, 2024·4 cites·18 claims
- 0296US11613585B2Nucleic acids encoding antagonistic CD40 monoclonal antibodiesBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Mar 28, 2023·3 cites·17 claims
- 0396US11254750B2Antagonistic CD40 monoclonal antibodies and uses in treating immune responsesBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Feb 22, 2022·6 cites·25 claims
- 0496US11220550B2Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activityBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jan 11, 2022·12 cites·15 claims
- 0594US12419953B2Methods of treatment or prevention of immune responses and inflammatory diseases with antagonistic CD40 monoclonal antibodiesBRISTOL MYERS SQUIBB CO·Filed 2024·Granted Sep 23, 2025·1 cites·20 claims
- 0694US11795231B2Antagonistic CD40 monoclonal antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Oct 24, 2023·2 cites·23 claims
- 0794US11773178B2Antagonistic CD40 monoclonal antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Oct 3, 2023·2 cites·17 claims
- 0894US10787494B2Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of useBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Sep 29, 2020·8 cites·8 claims
- 0992US11359000B2Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of useBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jun 14, 2022·5 cites·23 claims
- 1086US12409223B2Antagonistic CD40 monoclonal antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2023·Granted Sep 9, 2025·0 cites·18 claims
- 1186US2025179140A1Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of useBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 1285US11261258B2Antagonistic CD40 monoclonal antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 1, 2022·2 cites·14 claims
- 1379US12202872B2Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of useBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Jan 21, 2025·0 cites·15 claims
- 1477US2023322941A1Antagonistic CD40 Monoclonal Antibodies and Uses ThereofBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 1556US2023203177A1Antibody Variants with Improved Pharmacokinetic PropertiesBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 1655US2020148779A1MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITHBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 1753US2024325495A1Fusion proteins for the treatment of diseaseBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 1852US2023331860A1Method of Treating an Autoimmune Disease with Antagonistic CD40 Monoclonal AntibodiesBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 1939US2006030582A1Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activityDEMARTINO JULIE·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mary Struthers files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →